Cell Medica, a life sciences firm specialising in immunotherapies, has raised £50m ($78.85m) in its series B.
Investors in the round include Imperial Innovations, the technology transfer office of Imperial College London. Also joining the round are Invesco Perpetual and Woodford Investment Management. Innovations, which contributed £15m to the round, will now hold a 27.6% stake in the firm.
Innovations co-founded Cell Medica along with the firm’s CEO Gregg Sando in 2007. It previously invested in the company in a seed round the year it was formed, and then again in 2012 when it joined Invesco Perpetual and the Cancer Prevention and Research Institute of Texas in a series A worth $26.5m. At the same time, the Wellcome Trust became a shareholder through the conversion of a loan into equity.
Cell Medica is working on immunotherapy treatments, similar to oncology firms Juno Therapeutics and Adaptimmune. Its two products, Cytovir and Cytorex, looks to tackle infectious diseases and cancer, respectively. Cytovir looks to overcome immunosuppression in stem cell transplant patients through the infusion of T-cells from a healthy donor, while Cytorex is targeting Epstein Barr virus, which has been associated with numerous types of cancer. The latest round of funding will be used to further the development of both products.
Gregg Sando, Cell Medica’s CEO, said: “Immunotherapy is one of the most exciting and fast-moving areas in cancer research right now, and Cell Medica is at the forefront of developing a new paradigm for the safe and effective treatment of patients with advanced lymphomas. The Series B financing will enable the Company to launch and complete the CITADEL Phase 2 clinical trial as an important step towards regulatory approval both in the US and Europe.”
Imperial not immune to Cell Medica
Nov 26, 2014 •
LEADERSHIP SOCIETY
Informing, connecting, and transforming the global corporate venture capital ecosystem.The Global Corporate Venturing (GCV) Leadership Society’s mission is to help bridge the different strengths and ambitions of investors across industry sectors, geography, structure, and their returns.
More featured content
Halo has researchers on speed dial for corporates
Halo has researchers on speed dial for corporates
How does a corporate find the right university researcher or startup when it's trying to solve a critical problem? Halo has the answer.
How Basel supercharged its spinout rate
How Basel supercharged its spinout rate
Basel has quietly built a life sciences ecosystem that’s becoming hard to ignore.
Crumbling system, fragile lives: can spinouts help in the senior care crisis?
Crumbling system, fragile lives: can spinouts help in the senior care crisis?
From a chest-worn device to help with Parkinson's symptoms to stress measuring socks — here are the spinouts providing support for senior citizens.
Events
Webinar: Innovate to heal - What does the hospital of the future look like?
Apr 10, 2024
Online
Online
Events
GCV Institute: Landing the Value of Corporate Venturing
May 6 -
May 9, 2024
Online
May 9, 2024
Online
Events
GCV Institute: CVC Investment Programs
May 21 -
May 22, 2024
Online
May 22, 2024
Online
Events
GCV Symposium 2024
Jun 24 -
Jun 26, 2024
London (UK)
Jun 26, 2024
London (UK)
Events
Corporate Venture in Brasil 2024 – International Delegation to Brazil
Oct 28 -
Oct 30, 2024
São Paulo (Brazil)
Oct 30, 2024
São Paulo (Brazil)
Top News
test reg